Notice: wp_enqueue_style was called incorrectly. Scripts and styles should not be registered or enqueued until the wp_enqueue_scripts, admin_enqueue_scripts, or login_enqueue_scripts hooks. Please see Debugging in WordPress for more information. (This message was added in version 3.3.0.) in /appdata/www/lp.salesbuddy.io/wp-includes/functions.php on line 4196

Warning: Use of undefined constant REQUEST_URI - assumed 'REQUEST_URI' (this will throw an Error in a future version of PHP) in /appdata/www/lp.salesbuddy.io/wp-content/themes/rise/functions.php on line 73
Why Biotechnology Automation Needs Scaling Up For Growth
SalesBuddy
Interesting? Share it with your team

Why Biotechnology Automation Needs Scaling Up For Growth

Biotechnology is a very diverse field.

Biotechnology is both a very large and diverse business.

From gene editing and food genetics to innovative new medicines and treatments, the industry covers a wide range of medical, consumer and health technologies poised for growth.

One study estimates that by 2024, biotechnology as an industry will approach $775 billion in valuation—up from $400 billion in 2017.

But despite these numbers, biotech also has some unique business challenges. These challenges impact its advancement and make navigating the waters of growing a successful biotech company more difficult.

Top 3 Challenges of Growing Successful Biotech Companies:

There are at least 3 main challenges that Biotech companies face today.

1. Capital

Biotech is extremely capital intensive compared to other industries, often with billions of dollars of investment required to bring successful and profitable products to market. High failure rates throughout trial phases mean a smaller percentage of finished products make it to the end of the development cycle.

2. Fragmentation

The industry is fragmented in two ways. First, it consists of multi-billion-dollar companies as well as small startup companies just entering the market, many with limited product offerings. And second, biotechnology covers a wide range of sub-industries and often the only thing linking them is the term itself.

3. Safety Concerns

Products within biotechnology industries are more strictly and tightly regulated compared to other industries. With public safety (and in many cases, life and death at stake), biotech companies deal with an ocean of regulation before seeing their product reach market.

Industrial Automation Companies Don’t Understand Biotechnology

Industrial Automation companies don't seem to understand Biotech.

In dealing with these challenges, small companies looking to scale may lag in automating their industrial processes. Large companies may also find automation efforts for new production processes impeded by focusing so intently on the cost of product development and a strict regulatory environment. Combined, this reduces the time and resources available to implement automation regardless of the size of the enterprise.

Ironically, automation of critical production processes could be the one thing that, if implemented and managed correctly, could help mitigate the impact of the challenges discussed above. But with the hyper-focus on capital acquisition and usage, and the sea of safety and regulatory strictures, many industry professionals have had nowhere to turn.

The Path to A Solution

The biotech industry is inherently filled with educated and innovative professionals. And with the stakes in terms of human life and capital investment so high, who better to take control of automation requirements for their industry than the scientists who built the biotech industry and are developing the products of the future?

Engineers have traditionally designed industrial control systems across a wide number of industries. But biotech, with its critical challenges, also requires input and ownership from its core professionals who understand their product best.

WonderLogix Enterprise

The wonderlogix enterprise solution.

Designed specifically for biotech, WonderLogix Enterprise is an automation platform that does just that. The WonderLogix platform does not require any programming or engineering, yet helps mitigate the risk involved in dependency on outside engineering resources during critical or sensitive stages. And modules for the automation for biotech are pre-built, to bring a system up and running fast – a key consideration for small biotech startups wanting to do it right from the start.

The platform makes it possible to simulate bio-processes for feasibility in an industrial control setting, a big innovation for those wanting to improve ROI through a reduction of traditional Trial III failure rates. And by keeping the automation parameters in-house, the platform helps protect a company’s IP.

Wonderlogix allows users to confidently control their system automation and do it safely. The benefits that accrue to the user provide a better use of capital while reducing the regulatory compliance burden and building safety directly into the process. As a result, scientists and specialists within biotech are free to do what they do best.

To learn more about how The WonderLogix Enterprise platform addresses the challenges for biotech industries and allows scientists to drive automation, visit our page.

About the Author Michael Edgar

Leave a Comment: